시장보고서
상품코드
1271136

세계의 특발성 폐섬유증(IPF) 시장 : 출시약과 파이프라인약 평가, 임상시험, 경쟁 상황

Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

발행일: | 리서치사: GlobalData | 페이지 정보: 영문 72 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

GlobalData의 역학 예측에서 커버되고 있는 16개국에서 2023년에 IPF 진단을 받은 유병자 수는 49만 명을 넘어설 것으로 전망입니다.

세계의 특발성 폐섬유증(IPF) 시장에 대해 조사 분석했으며, 질환 상황, 출시약과 파이프라인약 평가, 현재와 향후 경쟁 상황 등을 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질환 상황

  • 질환 개요
  • 역학 개요
  • 치료 개요

제4장 출시약 평가

  • 주요 출시약
  • 개요 : 작용기서별
  • 개요 : 투여 경로별
  • 출시약 프로파일과 판매 예측

제5장 가격 설정과 상환 평가

  • 연간 치료비
  • 가격 설정과 상환까지 시간

제6장 파이프라인약 평가

  • 단계 3 파이프라인약
  • 개요 : 개발 단계별
  • 개요 : 분자 유형별
  • 개요 : 작용기서별
  • 개요 : 투여 경로별
  • 약품 고유의 단계 이동 성공률(PTSR)과 승인 가능성(LoA)
  • 치료 분야와 적응증 고유의 PTSR과 LoA

제7장 임상시험 평가

  • 과거 개요
  • 개요 : 단계별
  • 개요 : 상황별
  • 개요 : 진행중·계획중인 시험 단계별
  • 가상 컴포넌트를 사용한 시험
  • 지역적 개요
  • 단일국·다국간 시험 : 지역별
  • 상위 20개 스폰서와 내역 : 단계별
  • 상위 20개 스폰서와 내역 : 상황별
  • 개요 : 엔드포인트 상황별
  • 개요 : 인종·민족별
  • 등록 데이터
  • 시험 시설 상위 20개국
  • 세계의 주요 20개 시설
  • 실현 가능성 분석 - 지역적 개요
  • 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

  • 합병, 인수, 전략적 제휴 : 지역별
  • 최근의 합병, 인수, 전략적 제휴

제9장 상업적 평가

  • 주요 시장 기업

제10장 향후 시장 촉매

제11장 부록

KSM 23.05.16

Abstract

This reports provides a data-driven overview of the current and future competitive landscape in IPF therapeutics.

  • There will be more than 0.49 million diagnosed prevalent cases of IPF in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for IPF.
  • Currently, there are two leading marketed drugs for the treatment of IPF, with Roche and Boehringer Ingelheim being key players in the disease space.
  • R&D activity in IPF is steady, with one product in pre-registration stage and three products in Phase III development.
  • Commercial sponsors dominate clinical trial development in IPF, with the US emerging as the key country for conducting trials in this disease space.
  • Globally, deals involving partnerships were the most common type of deals involving companies developing
  • There will be more than 0.49 million diagnosed prevalent cases of IPF in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for IPF.
  • Currently, there are two leading marketed drugs for the treatment of IPF, with Roche and Boehringer Ingelheim being key players in the disease space.
  • R&D activity in IPF is steady, with one product in pre-registration stage and three products in Phase III development.
  • Commercial sponsors dominate clinical trial development in IPF, with the US emerging as the key country for conducting trials in this disease space.
  • Globally, deals involving partnerships were the most common type of deals involving companies developing IPF assets.

Scope

GlobalData's IPF: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the IPF market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

  • 1.1 Contents
  • 1.2 Report Scope
  • 1.3 List of Tables and Figures
  • 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

  • 3.1 Disease Overview
  • 3.2 Epidemiology Overview
  • 3.3 Treatment Overview

4 Marketed Drugs Assessment

  • 4.1 Leading Marketed Drugs
  • 4.2 Overview by Mechanism of Action
  • 4.3 Overview by Route of Administration
  • 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

  • 5.1 Annual Therapy Cost
  • 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

  • 6.1 Phase III Pipeline Drugs
  • 6.2 Overview by Development Stage
  • 6.3 Overview by Molecule Type
  • 6.4 Overview by Mechanism of Action
  • 6.5 Overview by Route of Administration
  • 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
  • 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

  • 7.1 Historical Overview
  • 7.2 Overview by Phase
  • 7.3 Overview by Status
  • 7.4 Overview by Phase for Ongoing and Planned Trials
  • 7.5 Trials with Virtual Components
  • 7.6 Geographic Overview
  • 7.7 Single-Country and Multinational Trials by Region
  • 7.8 Top 20 Sponsors with Breakdown by Phase
  • 7.9 Top 20 Sponsors with Breakdown by Status
  • 7.10 Overview by Endpoint Status
  • 7.11 Overview by Race and Ethnicity
  • 7.12 Enrollment Data
  • 7.13 Top 20 countries for Trial Sites
  • 7.14 Top 20 Sites Globally
  • 7.15 Feasibility Analysis - Geographic Overview
  • 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

  • 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
  • 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

  • 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

  • 11.1 Methodology
  • 11.2 Methodology - Sales Forecast
  • 11.3 Methodology - Pricing and Reimbursement
  • 11.4 Methodology - PTSR and LoA Analysis
  • 11.5 About the Authors
  • 11.6 Contact Us
  • 11.7 Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제